Ever-advancing chronic myeloid leukemia treatment (Q38164565)

30 August 2017

Ever-advancing chronic myeloid leukemia treatment (English)

1 reference

30 August 2017

chronic myeloid leukemia

0 references

1 reference

Shinya Kimura

1

1 reference

PubMed ID

24258348

30 August 2017

Toshihiko Ando

series ordinal

2

1 reference

PubMed ID

24258348

30 August 2017

Kensuke Kojima

series ordinal

3

1 reference

30 August 2017

22 November 2013

1 reference

International Journal of Clinical Oncology

30 August 2017

1 reference

30 August 2017

19

1 reference

30 August 2017

1

1 reference

30 August 2017

3-9

1 reference

https://scigraph.springernature.com/pub.10.1007/s10147-013-0641-7

30 August 2017

0 references

cites work

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0641-7

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0641-7

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0641-7

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0641-7

Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0641-7

Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0641-7

Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0641-7

Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0641-7

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0641-7

Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0641-7

BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0641-7

BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0641-7

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0641-7

Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0641-7

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0641-7

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0641-7

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0641-7

Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0641-7

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0641-7

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0641-7

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0641-7

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0641-7

Neuroprotective efficacy of a new brain-penetrating C-Abl inhibitor in a murine Parkinson's disease model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0641-7

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0641-7

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0641-7

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0641-7

SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24258348

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Second generation Abl kinase inhibitors and novel compounds to eliminate the Bcr-Abl/T315I clone

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24258348

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24258348

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10147-013-0641-7

1 reference

30 August 2017

1 reference

PubMed ID

24258348